25K0 Stock Chart & Stats
€1.53
-€0.05(-0.84%)
At close: 4:00 PM EDT
€1.53
-€0.05(-0.84%)
Day’s Range― - ―
52-Week Range€0.68 - €9.25
Previous CloseN/A
Volume0.00
Average Volume (3M)16.00
Market Cap
€16.22M
Enterprise Value€473.81M
Total Cash (Recent Filing)€65.11M
Total Debt (Recent Filing)€215.88M
Price to Earnings (P/E)―
Beta0.98
Next Earnings
Oct 29, 2026EPS Estimate
-0.84Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-22.32
Shares Outstanding22,681,460
10 Day Avg. Volume35
30 Day Avg. Volume16
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)-0.27
Price to Sales (P/S)0.55
P/FCF Ratio-1.07
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€5.83Price Target Upside280.75% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering6
EPS Forecast (FY)-4.24
Revenue Forecast (FY)€117.97M
Bulls Say, Bears Say
Bulls Say
Myelofibrosis Regulatory ProgressThe submitted sNDA creates a defined regulatory pathway for expanding selinexor into myelofibrosis. If FDA review and approval progress as planned, the indication could broaden the product’s addressable market and support a more durable commercial growth opportunity.
Strong Phase III Efficacy SignalStatistically significant spleen-volume reduction together with a favorable overall-survival signal strengthens the clinical rationale for the combination. These data may support adoption, regulatory validation, and longer-term value from selinexor if confirmatory evidence verifies the benefit.
Established Commercial PlatformAn existing hematology commercial infrastructure can reduce the execution burden of launching an additional selinexor indication. Established product experience, patient support, and market access relationships may improve the company’s ability to convert regulatory progress into recurring revenue.
Bears Say
Severe Liquidity And Covenant StressThe missed debt payment and finite liquidity runway create an immediate financing dependency that can disrupt operations and strategic execution. Continued forbearance, new capital, or a transaction is needed to avoid creditor remedies and the stated risk of bankruptcy or discontinued operations.
Stressed Capital StructureDeeply negative equity and debt that exceeds the asset base indicate limited balance-sheet resilience. This structure reduces financial flexibility, increases dependence on external funding, and can make future financing more costly or dilutive while the company remains loss-making.
Pipeline Diversification SetbackFailure of the endometrial cancer Phase III endpoint removes a potential growth avenue and concentrates future development success more heavily on myelofibrosis and existing XPOVIO demand. Reduced pipeline breadth increases execution risk if regulatory or confirmatory outcomes disappoint.
Karyopharm Therapeutics News
25K0 FAQ
What was Karyopharm Therapeutics’s price range in the past 12 months?
Karyopharm Therapeutics lowest stock price was €0.68 and its highest was €9.25 in the past 12 months.
What is Karyopharm Therapeutics’s market cap?
Karyopharm Therapeutics’s market cap is €16.22M.
When is Karyopharm Therapeutics’s upcoming earnings report date?
Karyopharm Therapeutics’s upcoming earnings report date is Oct 29, 2026 which is in 22 days.
How were Karyopharm Therapeutics’s earnings last quarter?
Karyopharm Therapeutics released its earnings results on Aug 13, 2026. The company reported -€2.064 earnings per share for the quarter, missing the consensus estimate of -€1.221 by -€0.843.
Is Karyopharm Therapeutics overvalued?
According to Wall Street analysts Karyopharm Therapeutics’s price is currently Undervalued.
Does Karyopharm Therapeutics pay dividends?
Karyopharm Therapeutics does not currently pay dividends.
What is Karyopharm Therapeutics’s EPS estimate?
Karyopharm Therapeutics’s EPS estimate is -0.84.
How many shares outstanding does Karyopharm Therapeutics have?
Karyopharm Therapeutics has 22,681,460 shares outstanding.
What happened to Karyopharm Therapeutics’s price movement after its last earnings report?
Karyopharm Therapeutics reported an EPS of -€2.064 in its last earnings report, missing expectations of -€1.221. Following the earnings report the stock price went down -5.233%.
Which hedge fund is a major shareholder of Karyopharm Therapeutics?
Currently, no hedge funds are holding shares in DE:25K0
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Karyopharm Therapeutics
Karyopharm Therapeutics Inc. is a pharmaceutical company that has already brought products to market, focusing on identifying, advancing, and selling medications designed to disrupt nuclear export pathways. These drugs are primarily aimed at treating cancer and various other illnesses. The company's strategy involves researching, creating, and marketing innovative Selective Inhibitor of Nuclear Export (SINE) compounds, which operate by attaching to and deactivating the nuclear export protein XPO1. Their leading therapeutic, XPOVIO, holds approvals for several critical applications in adult patients: it is prescribed in combination with bortezomib and dexamethasone for multiple myeloma; alongside dexamethasone for those with heavily pretreated multiple myeloma; and as a standalone treatment for relapsed or refractory diffuse large B-cell lymphoma. Karyopharm has also established a licensing partnership with the Menarini Group, granting them rights to develop and market NEXPOVIO for human oncology indications across Europe (including the United Kingdom), Latin America, and other global regions. Furthermore, the company's oral SINE compounds are specifically engineered to promote the accumulation of various tumor suppressor and growth-regulating proteins within the cell nucleus. Established in 2008, Karyopharm Therapeutics Inc. maintains its principal offices in Newton, Massachusetts.
25K0 Company Deck
25K0 Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call conveyed materially positive clinical and regulatory progress—most notably compelling Phase III SENTRY data, constructive FDA interactions around SVR35 as a surrogate endpoint, an on-track sNDA submission, publication/presentation of results, and steady XPOVIO commercial performance—positioning the company for a potential accelerated approval and a sizeable myelofibrosis market opportunity. Offsetting these positives are significant near-term financial risks: a missed endometrial cancer Phase III endpoint that reduced pipeline diversification, a widened reported net loss driven by non-cash financing impacts, limited cash runway (liquidity into September 2026) and an upcoming $15.8M loan payment that could trigger a covenant default without new financing or waivers. Regulatory timing uncertainty (need for long-term OS confirmatory data) and transitional expense pressures add further near-term risk. Overall, the call balanced strong clinical momentum and commercial readiness against pronounced short-term financial and execution risks.View all DE:25K0 earnings summaries25K0 Stock 12 Month Forecast
Average Price Target
€5.83
▲(280.75% Upside)
Technical Analysis
Actinium Pharmaceuticals
―
―
Lantern Pharma
―
Century Therapeutics
―
Medicus Pharma Ltd
―